Mazdutide vs. Tirzepatide: Analysis of Next-Gen Diabetes Treatments
In recent years, demand for effective treatments for type 2 diabetes and obesity led to advancements in pharmaceuticals. Mazdutide and tirzepatide are noteworthy contenders, attracting attention due to promising clinical trial results. Both are dual-incretin receptor agonists targeting GLP-1 and GIP receptors for glycemic control and weight loss.






